Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
Abstract
:1. Introduction
2. Material and Methods
2.1. Study Design
2.2. Data Collection and Definitions
2.3. Statistical Analysis
3. Results
3.1. Patient Population
3.2. PGD, Acute Rejection and CLAD
3.3. Infection
3.4. Side Effects and Death
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Scheffert, J.L.; Raza, K. Immunosuppression in lung transplantation. J. Thorac. Dis. 2014, 6, 1039–1053. [Google Scholar] [PubMed]
- Yusen, R.D.; Christie, J.; Edwards, L.B.; Kucheryavaya, A.Y.; Benden, C.; Dipchand, A.I.; Dobbels, F.; Kirk, R.; Lund, L.H.; Rahmel, A.O.; et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth adult lung and heart-lung transplant report 2013; focus theme: Age. J. Heart Lung Transplant. 2013, 32, 965–978. [Google Scholar] [CrossRef] [PubMed]
- Verleden, G.M.; Glanville, A.R.; Lease, E.D.; Fisher, A.J.; Calabrese, F.; Corris, P.A.; Ensor, C.R.; Gottlieb, J.; Hachem, R.R.; Lama, V.; et al. Chronic lung allograft dysfunction: Definition diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J. Heart Lung Transplant. 2019, 38, 493–503. [Google Scholar] [CrossRef] [PubMed]
- Chambers, D.C.; Perch, M.; Zuckermann, A.; Cherikh, W.S.; Harhay, M.O.; Hayes, D., Jr.; Hsich, E.; Khush, K.K.; Potena, L.; Sadavarte, A.; et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report—2021; Focus on recipient characteristics. J. Heart Lung Transplant. 2021, 40, 1060–1072. [Google Scholar] [CrossRef] [PubMed]
- Clinckart, F.; Bulpa, P.; Jamart, J.; Eucher, P.; Delaunois, L.; Evrard, P. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. Transpl. Proc. 2009, 41, 607–609. [Google Scholar] [CrossRef] [PubMed]
- Hachem, R.R.; Chakinala, M.M.; Yusen, R.D.; Lynch, J.P.; Aloush, A.A.; Patterson, G.A.; Trulock, E.P. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J. Heart Lung Transplant. 2005, 24, 1320–1326. [Google Scholar] [CrossRef] [PubMed]
- De la Torre, M.; Peña, E.; Calvin, M.; Miguélez, C.; González, D.; Fernández, R.; Molina, F.; Borro, J. Basiliximab in lung transplantation: Preliminary experience. Transpl. Proc. 2005, 37, 1534–1536. [Google Scholar] [CrossRef] [PubMed]
- Henry, M.L.; Rajab, A. The use of basiliximab in solid organ transplantation. Expert Opin. Pharmacother. 2002, 3, 1657–1663. [Google Scholar] [CrossRef] [PubMed]
- Palmer, S.M.; Miralles, A.P.; Lawrence, C.M.; Gaynor, J.W.; Davis, R.D.; Tapson, V.F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: Results of a randomized, prospective study. Chest 1999, 116, 127–133. [Google Scholar] [CrossRef] [PubMed]
- Garrity, E.R.; Villanueva, J.; Bhorade, S.M.; Husain, A.N.; Vigneswaran, W.T. Low rate of acute lung allograft rejection after the use of daclizumab an interleukin 2 receptor antibody. Transplantation 2001, 71, 773–777. [Google Scholar] [CrossRef] [PubMed]
- Ailawadi, G.; Smith, P.W.; Oka, T.; Wang, H.; Kozower, B.D.; Daniel, T.M.; Kron, I.L.; Jones, D.R. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. Thorac. Cardiovasc. Surg. 2008, 135, 594–602. [Google Scholar] [CrossRef] [PubMed]
- Hartwig, M.G.; Snyder, L.D.; Appel, J.Z.; Cantu, E.; Lin, S.S.; Palmer, S.M.; Davis, R.D. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J. Heart Lung Transplant. 2008, 27, 547–553. [Google Scholar] [CrossRef] [PubMed]
- Snell, G.I.; Yusen, R.D.; Weill, D.; Strueber, M.; Garrity, E.; Reed, A.; Pelaez, A.; Whelan, T.P.; Perch, M.; Bag, R.; et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2017, 36, 1097–1103. [Google Scholar] [CrossRef] [PubMed]
- A Yousem, S.; Berry, G.J.; Cagle, P.T.; Chamberlain, D.; Husain, A.N.; Hruban, R.H.; Marchevsky, A.; Ohori, N.P.; Ritter, J.; Stewart, S.; et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J. Heart Lung Transplant. 1996, 15, 1–15. [Google Scholar] [PubMed]
- Parulekar, A.D.; Kao, C.C. Detection, classification, and management of rejection after lung transplantation. J. Thorac. Dis. 2019, 11, 1732–1739. [Google Scholar] [CrossRef] [PubMed]
- Andrade-Sierra, J.; Heredia-Pimentel, A.; Rojas-Campos, E.; Flores, D.R.; Cerrillos-Gutierrez, J.I.; Miranda-Díaz, A.G.; Luis, A.; Evangelista, C.; Martínez-Martínez, P.; Jalomo-Martínez, B.; et al. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab. Int. J. Infect. Dis. 2021, 107, 18–24. [Google Scholar] [CrossRef] [PubMed]
ATG (n = 43) | BAS (n = 61) | NI (n = 20) | p Value | |
---|---|---|---|---|
Age, median [IQ] | 52.0 [15] | 52.0 [16] | 52.5 [28] | 0.767 |
Male sex, n (%) | 27 (62.8%) | 40 (65.6%) | 15 (75.0%) | 0.630 |
Bilateral, n (%) | 29 (67.4%) | 50 (82.0%) | 16 (80.0%) | 0.210 |
Indication for LTx, n (%) | ||||
COPD | 8 (18.6%) | 18 (29.5%) | 4 (20%) | |
IPF | 9 (20.9%) | 5 (8.2%) | 4 (20%) | |
CF | 6 (14.0%) | 8 (13.1%) | 3 (15%) | |
HP | 6 (14.0%) | 8 (13.1%) | 2 (10%) | |
BC | 4 (9.2%) | 5 (8.2%) | 6 (30%) | |
AATD | 4 (9.2%) | 2 (3.3%) | 1 (5%) | |
Others | 6 (14.0%) | 15 (24.6%) | 0 |
ATG (n = 43) | BAS (n =6 1) | NI (n = 20) | p Value ATG vs. BAS | |
---|---|---|---|---|
CMV infection, no (%) | 12 (27.9%) | 11 (18.0%) | 1 (5.0%) | 0.232 |
Pneumonia, no (%) | 31 (72.1%) | 41 (67.2%) | 15 (75.0%) | 0.595 |
Pathological agent | ||||
Achromobacter Xylosoxidans | 1 | |||
Acinetobacter Baumanii | 1 | |||
Aspergillus Falvus | 1 | |||
Aspergillus Fumigatus | 2 | 2 | ||
Aspergillus Niger | 1 | 1 | ||
Aspergillus Terreus | 1 | |||
Burkholeria Cepacia | 1 | |||
Candida Albicans | 1 | 4 | 3 | |
Candida Lusitaniae | 1 | |||
Candida Prapsilosis | 1 | |||
Candida Tropicalis | 1 | |||
Candida Krusei | 1 | |||
Citrobacter Koseri | 1 | |||
Enterobacter Aerogenes | 2 | 1 | ||
Enterobacter Clocae | 2 | |||
Haemophilus influenzae | 1 | |||
Influenzae | 1 | |||
Klebsiella ESBL+ | 1 | 2 | 1 | |
Klebsiella Oxytoca | 1 | 1 | 1 | |
Klebsiella OXA 48 | ||||
Klebsiella Pneumoniae | 2 | 8 | 3 | |
KPC | 1 | 1 | ||
Moraxella Catarrhalis | 1 | |||
Morganella Morganii | 1 | |||
MRSA | 2 | 3 | ||
MSSA | 4 | 3 | 2 | |
Mycobacterium Tuberculosis | 1 | 1 | ||
Pneumocystis Jirovecii | 2 | |||
Proteus Mirabilis | 1 | |||
Pseudomonas Aeruginosas | 10 | 11 | 5 | |
Serratia Marescens | 2 | |||
Streptococcus Pneumoniae | 1 | 1 | ||
Staphylococcus Epidermidis | 1 | |||
Staphylococcus Haemolyticus | 1 | |||
Stenotrophormonas Maltophilia | 3 | 1 | 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mendes, B.; Figueiredo, C.; Cabral, M.; Borba, A.; Mineiro, A.; Cardoso, J.; Calvinho, P.; Semedo, L.; Fragata, J. Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review. Transplantology 2022, 3, 267-274. https://doi.org/10.3390/transplantology3030027
Mendes B, Figueiredo C, Cabral M, Borba A, Mineiro A, Cardoso J, Calvinho P, Semedo L, Fragata J. Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review. Transplantology. 2022; 3(3):267-274. https://doi.org/10.3390/transplantology3030027
Chicago/Turabian StyleMendes, Bruno, Carlos Figueiredo, Mariana Cabral, Alexandra Borba, Alexandra Mineiro, João Cardoso, Paulo Calvinho, Luísa Semedo, and José Fragata. 2022. "Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review" Transplantology 3, no. 3: 267-274. https://doi.org/10.3390/transplantology3030027
APA StyleMendes, B., Figueiredo, C., Cabral, M., Borba, A., Mineiro, A., Cardoso, J., Calvinho, P., Semedo, L., & Fragata, J. (2022). Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review. Transplantology, 3(3), 267-274. https://doi.org/10.3390/transplantology3030027